Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for AbCellera, Databricks, and 370+ companies. 5-min read every Tuesday.
Antibody discovery platform using AI and microfluidics to rapidly identify therapeutic antibodies at scale.
| Industry | Biotechnology |
| Stage | Public |
| IPO Status | Public |
| Valuation | $1.2B |
| Total Funding | $105M |
| Headquarters | Vancouver, BC, Canada |
Databricks is the world's most valuable data and AI platform — $134B valuation, $4.2B raised. Widely expected to IPO. Track readiness score and timeline.
| Industry | Enterprise Software |
| Stage | Pre-IPO |
| IPO Status | Pre-IPO |
| Valuation | $134B |
| Total Funding | $19B |
| Headquarters | San Francisco, CA |
AbCellera is valued at $1.2B. Databricks is valued at $134B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
AbCellera has raised $105M. Databricks has raised $19B.
AbCellera is currently already public. Databricks is currently pre-IPO. Track both on TechStackIPO for S-1 filings and IPO announcements.
AbCellera operates in Biotechnology, while Databricks operates in Enterprise Software.
AbCellera is a Biotechnology company valued at $1.2B with $105M raised. Databricks is a Enterprise Software company valued at $134B with $19B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in AbCellera and Databricks through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.